PMID- 35506035
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1428-2526 (Print)
IS  - 1897-4309 (Electronic)
IS  - 1428-2526 (Linking)
VI  - 26
IP  - 1
DP  - 2022
TI  - Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin 
      (beta)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell 
      non-Hodgkin lymphoma patients - an immunohistochemical study.
PG  - 49-58
LID - 10.5114/wo.2022.115675 [doi]
AB  - INTRODUCTION: Diffuse large B-cell non- Hodgkin lymphoma (DLBCL) is the largest 
      common category of adult lymphoma. Recurrence and treatment resistance occurs in 
      one-third of cases, triggering them to the progressive stage of DLBCL after 
      treatment. Detection of novel predictive and prognostic biomarkers leads to 
      improvement of its treatment and prognosis. AIM OF THE STUDY: To assess the 
      prognostic roles of protein expression of myeloid differentiation factor 88 
      (MYD88) and transducin (beta)-like receptor 1 (TBLR1) in tissues of DLBCL patients. 
      MATERIAL AND METHODS: In the current study we included tissues from 100 cases of 
      DLBCL. For immunohistochemistry, tissues were stained with MYD88 and TBLR1. We 
      followed patients for about 3 years, and then we correlated their expression with 
      clinicopathological and prognostic parameters. RESULTS: Higher MYD88 and TBLR1 
      expressions were associated with presence of B symptoms, fever, night sweat, 
      advanced stage, bone marrow involvement and bulky nodal size, presence of 
      extra-nodal extension, unfavourable relapse-free survival, and unfavourable 
      overall survival rates (p < 0.001). CONCLUSIONS: overexpression of MYD88 and 
      TBLR1 expression was present in DLBCL patients and was associated with 
      unfavourable clinicopathological and prognostic parameters.
CI  - Copyright (c) 2022 Termedia.
FAU - Mohamed, Asmaa Hussein
AU  - Mohamed AH
AD  - Department of Pathology, Zagazig University Faculty of Medicine, Zagazig, Egypt.
FAU - Elfeky, Mariem A
AU  - Elfeky MA
AD  - Department of Pathology, Zagazig University Faculty of Medicine, Zagazig, Egypt.
FAU - Elshorbagy, Shereen
AU  - Elshorbagy S
AD  - Department of Medical Oncology, Faculty of Medicine, Zagazig University Zagazig, 
      Egypt.
FAU - Hefzi, Nabila
AU  - Hefzi N
AD  - Department of Clinical Oncology Oncology, Faculty of Medicine, Zagazig University 
      Zagazig, Egypt.
FAU - Oraby, Tamer
AU  - Oraby T
AD  - Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, 
      Zagazig, Egypt.
FAU - Abdelhady, Waleed A
AU  - Abdelhady WA
AD  - Department of General Surgery, Faculty of Medicine, Zagazig, Egypt.
FAU - Eldein, Mahmoud Sharaf
AU  - Eldein MS
AD  - Department of Internal Medicine, Faculty of Medicine, Zagazig, Egypt.
FAU - Embaby, Ahmed
AU  - Embaby A
AD  - Department of Internal Medicine, Faculty of Medicine, Zagazig, Egypt.
FAU - Oraby, Ehab M
AU  - Oraby EM
AD  - Department of General Surgery, Faculty of Medicine, Benha, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20220330
PL  - Poland
TA  - Contemp Oncol (Pozn)
JT  - Contemporary oncology (Poznan, Poland)
JID - 101233223
PMC - PMC9052345
OTO - NOTNLM
OT  - MYD88
OT  - TBLR1
OT  - diffuse large B-cell lymphoma
OT  - immunohistochemistry
OT  - prognosis
COIS- The authors declare no conflict of interest.
EDAT- 2022/05/05 06:00
MHDA- 2022/05/05 06:01
PMCR- 2022/01/01
CRDT- 2022/05/04 02:21
PHST- 2021/10/29 00:00 [received]
PHST- 2022/02/08 00:00 [accepted]
PHST- 2022/05/04 02:21 [entrez]
PHST- 2022/05/05 06:00 [pubmed]
PHST- 2022/05/05 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 46893 [pii]
AID - 10.5114/wo.2022.115675 [doi]
PST - ppublish
SO  - Contemp Oncol (Pozn). 2022;26(1):49-58. doi: 10.5114/wo.2022.115675. Epub 2022 
      Mar 30.